IDXG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IDXG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Interpace Biosciences's share price is $1.42. Interpace Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.55. Hence, Interpace Biosciences's Price-to-Free-Cash-Flow Ratio for today is 2.61.
The historical rank and industry rank for Interpace Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Interpace Biosciences's highest Price-to-Free-Cash-Flow Ratio was 6.09. The lowest was 1.72. And the median was 2.97.
Interpace Biosciences's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.23. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.55.
During the past 13 years, Interpace Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 70.80% per year. The lowest was -82.00% per year. And the median was 27.25% per year.
The historical data trend for Interpace Biosciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | 1.42 |
Interpace Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | 4.54 | 1.42 |
For the Diagnostics & Research subindustry, Interpace Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Price-to-Free-Cash-Flow falls into.
Interpace Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 1.42 | / | 0.545 | |
= | 2.61 |
Interpace Biosciences's Share Price of today is $1.42.
Interpace Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Interpace Biosciences (OTCPK:IDXG) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Interpace Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Mccarthy | officer: Principal Financial Officer | C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054 |
Vijay Aggarwal | director | 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405 |
Thomas W. Burnell | director, officer: President and CEO | 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309 |
Peter H Kamin | 10 percent owner | 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410 |
Fred S. Knechtel | officer: Chief Financial Officer | REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064 |
Fortunato R. Rocca | director | C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081 |
Edward Chan | director | C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104 |
1315 Capital Ii, L.p. | 10 percent owner | 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104 |
Robert J. Gorman | director | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Laurence Mccarthy | director | 2110 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Ampersand 2018 Limited Partnership | 10 percent owner | 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481 |
Eric B. Lev | director, 10 percent owner | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Thomas John Freeburg | officer: Chief Accounting Officer | INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054 |
Gregory Richard | officer: Chief Commerical Officer | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054 |
Felice Schnoll-sussman | director | C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054 |
From GuruFocus
By Value_Insider Value_Insider • 10-20-2022
By Marketwired Marketwired • 04-22-2021
By Don Li2 Don Li2 • 11-02-2021
By GuruFocusNews GuruFocusNews • 06-10-2022
By GlobeNewswire GlobeNewswire • 09-01-2022
By Ds*** Ds*** • 09-01-2022
By GuruFocusNews GuruFocusNews • 01-03-2022
By GlobeNewswire GlobeNewswire • 01-12-2022
By sperokesalga sperokesalga • 05-12-2023
By GuruFocusNews GuruFocusNews • 01-29-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.